Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 16.82 as of 2026-10-06T20:35:50.636Z.
Consensus retrieved: 2026-10-06T09:46:27.102Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:35:50.636Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 10ac25c4caca98f46ae67912a93dca33de3b4cdb011bd33a21929391617ca96b
Forward PE Ratio (16.82) = Dated Quote Price ($13.10) / Consensus Forward EPS ($0.78)
FORWARD PE RATIO
16.82
SECTOR MEDIAN · HEALTHCARE
19.79
median of 190 covered companies
CURRENT VS SECTOR MEDIAN
-14.99%
vs the sector median at left
Bioventus Inc.
Market Cap
$887.50M
Forward PE Ratio
16.82
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Bioventus Inc. (BVS) | $887.50M | 16.82 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 6.05 |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | N/A |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.73M | 42.43 |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | 16.27 |
| Alumis Inc. (ALMS)vs › | $855.38M | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $921.06M | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 13.44 |
Trailing P/E
17.0
reported TTM EPS
Forward P/E
16.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.78 implies +1.3% EPS growth vs the reported trailing $0.77.
At the dated quote price of $13.10, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.78 | $0.77 – $0.79 | 4 | 16.8x |
| 2027-12-31 | $0.92 | $0.91 – $0.93 | 4 | 14.2x |
| 2028-12-31 | $1.06 | $0.79 – $1.40 | 4 | 12.3x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
